Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edwin Robinson

Family Medicine Richmond, VA Medical Doctor

NPI 1306841564 CMS profile 240441

1800 Glenside Dr, Suite 105, Richmond, VA 23226

Open in the dashboard

General payments

$83,244

644 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edwin Robinson of Richmond, VA is reported in the CMS Open Payments database as having received $83,244 across 644 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,619 87
2024 General $3,510 123
2023 General $4,335 104
2022 General $18,506 107
2021 General $33,490 129
2020 General $16,124 50
2019 General $4,660 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edwin Robinson
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Edwin Robinson were reported at $2,619. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Edwin Robinson Family Medicine median Middle half National median
2019 $4,660 $150 $41–$543 $163
2020 $16,124 $120 $32–$415 $114
2021 $33,490 $137 $35–$551 $132
2022 $18,506 $137 $37–$512 $149
2023 $4,335 $149 $42–$545 $160
2024 $3,510 $156 $44–$560 $164
2025 $2,619 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $71,289 146 payments
  2. AstraZeneca Pharmaceuticals LP $2,243 40 payments
  3. AbbVie, Inc. $1,463 50 payments
  4. Amgen Inc. $981 68 payments
  5. Novo Nordisk Inc $868 46 payments
  6. Lilly USA, LLC $812 46 payments
  7. Phathom Pharmaceuticals, Inc. $511 13 payments
  8. Pfizer Inc. $457 31 payments
  9. Abbott Laboratories $377 16 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $373 20 payments
  11. Other $3,870 168 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $70,967 140 payments
  2. Food and Beverage $12,028 501 payments
  3. Travel and Lodging $244 2 payments
  4. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. GILENYA Neuroscience $55,666 110 payments
  2. MAYZENT Neuroscience $13,401 28 payments
  3. GILENYA Neurology $1,194 3 payments
  4. BREZTRI $1,012 14 payments
  5. MAYZENT Neurology $950 1 payment
  6. AIRSUPRA $887 12 payments
  7. UBRELVY $842 35 payments
  8. FARXIGA $787 16 payments
  9. QULIPTA $784 31 payments
  10. Ozempic $593 32 payments
  11. Other $10,976 570 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

952

Median for Family Practice: 1,826

Drug cost

$7,132

Median for Family Practice: $120,094

Branded share of claims

29.4%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 113 $1,005
Neomycin-Polymyxin-Hydrocort Neomycin/Polymyxin B/Hydrocort Brand 13 $794
Prednisone Generic 107 $751
Albuterol Sulfate Hfa Albuterol Sulfate Brand 39 $729
Azithromycin Generic 153 $593
Oseltamivir Phosphate Generic 19 $397
Amoxicillin Generic 108 $394
Methylprednisolone Generic 71 $383
Sulfacetamide Sodium Generic 12 $362
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 40 $332

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$76,658

Of which drugs: $666

Medicare patients

890

Average age 75

Services billed

2,440

551 women, 339 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 44%
Ischemic heart disease 25%
Depression 24%
Diabetes 22%
Cancer 18%
Chronic kidney disease 17%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for tetanus and diphtheria toxoids injection into muscle, patient 7 years or older 90714 Office 15 15 $240

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 44 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $444
$444 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $318
$318 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $215
$215 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $171
$171 — —
MOUNJARO
  • Lilly USA, LLC $158
$158 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 44 with Patron

Records

644 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record